

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: PELLICER=1A

In re Application of:

PELLICER et al.

Appln. No.: 10/625,471

Filed: July 23, 2003

For: HUMAN RGR ONCOGENE AND TRUNCATED TRANSCRIPTS THEREOF DETECTED IN...

Art Unit: 1632

Description of:

No.: 1686

Description No.: 1632

Description of:

No.: 1686

Description No.: 1632

Description of:

No.: 1686

Description No.: 1686

Description of:

No.: 1686

Description No.: 1686

Descri

## INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents U.S. Patent and Trademark Office 2011 South Clark Place Customer Window, Mail Stop Crystal Plaza Two, Lobby, Room 1B03 Arlington, Virginia 22202

## Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed before the mailing date of a first Office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114.

In re Appln. No. 10/625,471

- 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., Form PTO/SB/08A) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.
- 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).
- 4. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK Attorneys for Applicant(s)

By:

Allen C. Yun Reg. No. 37,971

ACY:pp

624 Ninth Street, N.W., Suite 300

Washington, D.C. 20001-5303

Telephone: (202)628-5197 Facsimile: (202)737-3528 G:\BN\N\nyum\PELLICERIA\pto\IDS.doc

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO 10/625,471 **Application Number** INFORMATION DISCLOSURE Filing Date July 23, 2003 PELLICER et al. STATEMENT BY APPLICANT First Named Inventor **Group Art Unit** (use as many sheets as necessary) **Examiner Name** Sheet Attorney Docket Number PELLICER=1A

	OTHER PRIOR ART. NON RATEUT LITERATURE ROOMINGS.				
	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>		
	AA	COROMINAS et al., Oncogene involvement in tumor regression: <i>H-ras</i> activation in the rabbit keratoacanthoma model, <u>Oncogene</u> , 6:645-651 (1991)			
	АВ	D'ADAMO et al., rsc: A novel oncogene with structural and functional homology with the gene family of exchange factors for Ral, Oncogene, 14:1295-1305 (1997)			
	AC	HERNANDEZ-MUÑOZ et al., The Rgr oncogene (homologous to RalGDS) induces transformation and gene expression by activating Ras, Ral and Rho mediated pathways, <u>Oncogene</u> , 19:2745-2757 (2000)			
	AD	MALUMBRES et al., Cellular response to oncogenic Ras involves induction of the Cdk4 and Cdk6 inhibitor p15 <sup>INK4b</sup> , Molecular and Cellular Biology, 20(8)2915-2925 (2000)			

Examiner	Date
Signature	Considered

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.